Technology transfer / Localization · GCC · Announced 13 Oct 2026
Sandoz → Tabuk Pharmaceuticals
Sandoz has signed a strategic partnership with Tabuk Pharmaceuticals to localize specialized medicines in Saudi Arabia — sponsored by the Kingdom's local-content and procurement authority, the body that shapes who wins public-sector volume.
Parties: Sandoz (Switzerland) → Tabuk Pharmaceuticals (Saudi Arabia)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Saudi Arabia
- Therapeutic area
- Multi-therapy
- Asset
- Specialized pharmaceutical products for local manufacture in Saudi Arabia (portfolio not disclosed)
- Announced
- 13 Oct 2026
Our analysis
Why this matters
Sandoz, one of the world's largest generics and biosimilars companies, has signed a strategic partnership with Tabuk Pharmaceuticals to localize the manufacture of specialized medicines in Saudi Arabia. The agreement was signed at the headquarters of the Local Content and Government Procurement Authority (LCGPA), which sponsored it, in the presence of LCGPA CEO Abdulrahman Al-Samari.
The sponsor is the signal. LCGPA sets the local-content preferences applied in Saudi government procurement, and the Kingdom's unified public tenders increasingly reward products made in-country. A multinational that wants to keep winning Saudi public-sector volume for specialty generics now needs a local manufacturing story — and the fastest route to one is an established Saudi plant, not a greenfield site.
The full analysis is free to read with a work email on this page.